Recent studies have suggested that dipeptidyl peptidase-4 inhibitors (DPP4-is), an incretin-based drug for type 2 diabetes, as possible predisposing agents of BP [2, 3]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.